BackX.T.L. Biopharmaceuticals Overview

X.T.L. Biopharmaceuticals Long Term Debt

Latest long-term debt for XTLB: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

X.T.L. Biopharmaceuticals Long Term Debt History

Loading

X.T.L. Biopharmaceuticals vs. peers: Long Term Debt Comparison

Loading

X.T.L. Biopharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

X.T.L. Biopharmaceuticals (XTLB) FAQ

X.T.L. Biopharmaceuticals (XTLB) currently reports a long-term debt of $0 as of December 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore X.T.L. Biopharmaceuticals's long-term debt history and peer comparisons.

X.T.L. Biopharmaceuticals's long-term debt changed from $0 to $0 (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

X.T.L. Biopharmaceuticals reported $0 in long-term debt as of December 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for X.T.L. Biopharmaceuticals, and consider following XTLB for alerts when major investors trade the stock.

X.T.L. Biopharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XTLB with unrelated industries.